Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Hologic, Inc. (NASDAQ: HOLX) is set to showcase its innovative breast and skeletal health solutions at the European Congress of Radiology in Vienna from July 13-17. The company aims to address challenges in early detection caused by pandemic delays. Attendees can explore Hologic's 3D Mammography™ technology and participate in scientific talks at the Scientific Innovation Hub. Highlights from the inaugural Hologic Global Women’s Health Index will also be shared, focusing on women's health perspectives. This event underscores Hologic's commitment to improving women's health.
Hologic, Inc. (Nasdaq: HOLX) has launched its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Novodiag® RESP-4 assay in the European Union, enhancing its molecular diagnostics offerings for the upcoming respiratory viral season. These assays identify four prevalent respiratory viruses, using nasopharyngeal swab samples. The products comply with EU regulations and aim to improve patient care by allowing healthcare providers to differentiate between similar viral infections. This marks a significant expansion in Hologic's diagnostic capabilities following the acquisition of Mobidiag.
Hologic, Inc. (NASDAQ: HOLX) will release its third quarter fiscal 2022 financial results on July 27, after market close. A conference call is scheduled for 4:30 p.m. ET that day. Interested parties can join by calling 800-289-0720 in the U.S. or +1-323-701-0160 internationally, using access code 6025981. The call will also be available via a live webcast on the company's investor website, and an archived replay will be provided after the call for 30 days.
Summary not available.
Hologic, Inc. (Nasdaq: HOLX) has received CE marking for its new Panther Fusion EBV and BKV Quant Assays, expanding its transplant pathogen monitoring capabilities. These in vitro nucleic acid amplification tests enable accurate quantitation of Epstein-Barr Virus and BK Virus in transplant patients, crucial for diagnosis and treatment management. The Panther Fusion system processes whole blood and plasma samples, which are vital for monitoring viral levels. This marks a significant addition as the first quantitative assays from Hologic's Liege facility.
Summary not available.
Hologic, Inc. (NASDAQ: HOLX) recently announced FDA approval for its Aptima CMV Quant assay, the first quantitative test for monitoring cytomegalovirus (CMV) in solid organ and stem cell transplant patients. This innovative test enhances patient outcomes by providing standardized clinical information and is fully automated on the Panther® system. With existing capabilities for viral load testing in HIV-1 and Hepatitis, Hologic aims to improve the management of transplant patients susceptible to infections. Future assays for BK Virus and Epstein-Barr Virus are in development.
Hologic, Inc. (NASDAQ: HOLX) will be participating in two key investor conferences. The Bank of America 2022 Healthcare Conference is scheduled for May 10 at 8:00 a.m. Pacific Time, while the William Blair 42nd Annual Growth Stock Conference is set for June 7 at 2:00 p.m. Central Time. Both presentations will be available via live webcast on Hologic's investor website, accessible for 30 days post-event. Hologic focuses on advancing women’s health through innovative medical technologies.
Hologic reported Q2 fiscal 2022 revenue of $1.436 billion, a 6.6% decline compared to the previous year, primarily due to lower COVID-19 assay sales. However, this figure exceeded the company's guidance of $1.25 to $1.3 billion. GAAP diluted EPS was $1.80, down 24.4% year-over-year, with non-GAAP diluted EPS at $2.07. Despite declines in various segments, the company raised its full-year revenue and EPS guidance, reflecting strong cash flow from operations of $1.062 billion and a robust balance sheet.
Hologic announces that the American Society of Clinical Oncology (ASCO) has updated its guidelines to include Breast Cancer Index™ (BCI) as the only genomic test for determining extended endocrine therapy in early-stage, HR+ breast cancer patients. This guideline aims to help healthcare providers make informed treatment decisions after five years of primary therapy. BCI is recognized for its ability to predict which patients may benefit from continued treatment, mitigating unnecessary side effects associated with extended therapy.